Benjamin Harrison
About Benjamin Harrison
Benjamin Harrison serves as the International Finance Manager at Aimmune Therapeutics in Lausanne, Switzerland, a position he has held since 2022. He has an extensive educational background, including multiple degrees from institutions such as the University of Aberdeen and Drew University, and has held various finance-related roles at Nestlé and Atlantic Health.
Work at Aimmune Therapeutics
Benjamin Harrison has been serving as the International Finance Manager at Aimmune Therapeutics since 2022. His role is based in Lausanne, Vaud, Switzerland. In this position, he manages international financial operations, contributing to the company's global financial strategy.
Education and Expertise
Benjamin Harrison holds a Master's degree in History from the University of Aberdeen, which he completed from 2010 to 2014. He also earned a Master's degree from the University of Aberdeen in 2016-2017. Additionally, he studied Economics and Neuroscience at Drew University, obtaining a Bachelor's degree from 2015 to 2017. His educational background includes studies in Business Administration at County College of Morris from 2013 to 2015.
Professional Background
Prior to his current role, Benjamin Harrison held several positions in finance. He worked as a Senior Financial Analyst at Nestlé Health Science from 2018 to 2019. He also served as an Advanced Staff Internal Auditor at Nestlé from 2019 to 2020 and as an Audit Team Lead from 2020 to 2022. Earlier in his career, he was a Finance and Data Analyst at Atlantic Health from 2016 to 2017 and a Financial Analyst at Nestlé Health Science from 2017 to 2018.
Career Progression
Benjamin Harrison's career in finance has shown a consistent progression through various roles. He began as a Finance and Data Analyst and advanced to positions such as Financial Analyst and Senior Financial Analyst at Nestlé Health Science. His experience culminated in leadership roles, including Audit Team Lead, before transitioning to his current position at Aimmune Therapeutics.